{
    "body": "Is JTV519 (K201) a potential drug for the prevention of arrhythmias?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20581784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15584870", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21291389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22001562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23144205", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22563249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20080988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17644079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15073377", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17994112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11090108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12890053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16672364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16185151"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A16995906", 
            "o": "C109183"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17004235", 
            "o": "JTV-519"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/label/A7798511"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/label/A17004235"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7798511", 
            "o": "JTV519"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/label/A16995906"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A16995906", 
            "o": "JTV 519"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/prefMetaMap", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/label/A7798511"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17004235", 
            "o": "C109183"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7798511", 
            "o": "C109183"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A16995906", 
            "o": "MeSH"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17004235", 
            "o": "MeSH"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#note", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7798511", 
            "o": "MeSH"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#broader", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/id/C0668089"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A1334561", 
            "o": "K-201"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A1362694", 
            "o": "K201 compound"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#narrower", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0668089", 
            "o": "http://linkedlifedata.com/resource/umls/id/C0754680"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/relation", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls/relation/R32009562"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#inScheme", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0754680", 
            "o": "http://linkedlifedata.com/resource/umls"
        }, 
        {
            "p": "http://linkedlifedata.com/resource/umls/relatedConcept", 
            "s": "http://linkedlifedata.com/resource/umls/relation/R32161252", 
            "o": "http://linkedlifedata.com/resource/umls/id/C0754680"
        }
    ], 
    "ideal_answer": [
        "Yes, JTV519 has antiarrhythmic properties."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000889"
    ], 
    "type": "yesno", 
    "id": "52b2f1724003448f5500000b", 
    "snippets": [
        {
            "offsetInBeginSection": 330, 
            "offsetInEndSection": 636, 
            "text": "We compared the suppressive effect of K201 (JTV519), a multiple-channel blocker and cardiac ryanodine receptor-calcium release channel (RyR2) stabilizer, with that of diltiazem, a Ca(2+ )channel blocker, in 2 studies of isoproterenol-induced (n = 30) and ischemic-reperfusion-induced VAs (n = 38) in rats. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1055, 
            "offsetInEndSection": 1584, 
            "text": "After administration of isoproterenol under Ca(2+) loading, fatal VA frequently occurred in the vehicle (9 of 10 animals, 90%) and diltiazem (8 of 10, 80%) groups, and K201 significantly suppressed the incidences of arrhythmia and mortality (2 of 10, 20%). In the reperfusion study, the incidence and the time until occurrence of reperfusion-induced VA and mortality were significantly suppressed in the K201 (2 of 15 animals, 13%) and diltiazem (1 of 9 animals, 11%) groups compared to the vehicle group (8 of 14 animals, 57%). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1707, 
            "offsetInEndSection": 1860, 
            "text": "K201 markedly suppressed both the isoproterenol-induced and the reperfusion-induced VAs, whereas diltiazem did not suppress the isoproterenol-induced VA.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144205", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1614, 
            "offsetInEndSection": 1876, 
            "text": "JTV519 (K201) is a newly developed 1,4-benzothiazepine drug with antiarrhythmic and cardioprotective properties. It appears to be very effective in not only preventing but also in reversing the characteristic myocardial changes and preventing lethal arrhythmias.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563249", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 389, 
            "text": "The novel antiarrhythmic drug K201 (4-[3-{1-(4-benzyl)piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine monohydrochloride) is currently in development for treatment of atrial fibrillation. K201 not only controls intracellular calcium release by the ryanodine receptors, but also possesses a ventricular action that might predispose to torsade de pointes arrhythmias. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22001562", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 969, 
            "offsetInEndSection": 1152, 
            "text": "The RyR is currently used as a therapeutic target in malignant hyperthermia where dantrolene is effective and to relieve ventricular arrhythmia, with the use of JTV519 and flecainide.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21291389", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1200, 
            "offsetInEndSection": 1372, 
            "text": "Finally, KN-3 and JTV519, two compounds that stabilize RyR2 in the closed state, prevent the induction of triggered activity and suppress the inducibility of sustained AF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581784", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1639, 
            "offsetInEndSection": 1718, 
            "text": "JTV-519 greatly reduced the frequency of ouabain-induced arrhythmogenic events.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080988", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1914, 
            "offsetInEndSection": 1995, 
            "text": "Stabilization of RyR2 by JTV-519 effectively reduces these triggered arrhythmias.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080988", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1473, 
            "offsetInEndSection": 1537, 
            "text": "These findings may reveal the anti-arrhythmic potential of K201.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994112", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 225, 
            "offsetInEndSection": 340, 
            "text": "The preferential ryanodine receptor stabilizer (K201) possesses antiarrhythmic effects through calcium regulation. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994112", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 153, 
            "text": "The drug K201 (JTV-519) increases inotropy and suppresses arrhythmias in failing hearts, but the effects of K201 on normal hearts is unknown. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644079", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1510, 
            "offsetInEndSection": 1616, 
            "text": "K201 fails to prevent DADs in RyR2(R4496C+/-) myocytes and ventricular arrhythmias in RyR2(R4496C+/-) mice", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16825580", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1071, 
            "offsetInEndSection": 1198, 
            "text": "In vivo administration of K201 failed to prevent induction of polymorphic ventricular tachycardia (VT) in RyR2(R4496C+/-) mice.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16825580", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 893, 
            "offsetInEndSection": 1089, 
            "text": "The 1,4-benzothiazepine JTV519, which increases the binding affinity of calstabin-2 for RyR2, inhibited the diastolic SR Ca2+ leak, monophasic action potential alternans and triggered arrhythmias.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16672364", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 499, 
            "offsetInEndSection": 720, 
            "text": "In arrhythmias, the calstabin2 stabiliser JTV519 did not prevent arrhythmias in calstabin2-/- mice, but reduced the arrhythmias in calstabin2+/- mice, illustrating the antiarrhythmic potential of stabilising calstablin2. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16185151", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 412, 
            "offsetInEndSection": 652, 
            "text": "In three models of arrhythmias, the calstabin2 stabiliser JTV519 did not prevent arrhythmias in calstabin2(-/-) mice, but reduced the arrhythmias in calstabin2(+/-) mice, illustrating the antiarrhythmic potential of stabilising calstabin2. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15584870", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 456, 
            "offsetInEndSection": 645, 
            "text": "A derivative of 1,4-benzothiazepine (JTV519) increased the affinity of calstabin2 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca2+ leak that triggers arrhythmias. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15073377", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1480, 
            "offsetInEndSection": 1732, 
            "text": "JTV-519 had significant protective effects on atrial fibrillation in the canine sterile pericarditis model, mainly by increasing effective refractory period, suggesting that it may have potential as a novel antiarrhythmic agent for atrial fibrillation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12890053", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 871, 
            "offsetInEndSection": 1002, 
            "text": "JTV-519 significantly decreased the mean number of sustained atrial fibrillation episodes (from 4.2 +/- 2.9 to 0 +/- 0, P < 0.01). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12890053", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1652, 
            "offsetInEndSection": 1851, 
            "text": "We conclude that JTV-519 can exert antiarrhythmic effects against AF by inhibiting repolarizing K(+) currents. The drug may be useful for the treatment of AF in patients with ischaemic heart disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11090108", 
            "endSection": "abstract"
        }
    ]
}